Compare Aptiv PLC (APTV) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Humana Inc — how do they compare? Aptiv PLC trades at $59.16 (market cap $12.82B), while Humana Inc trades at $405 (market cap $47.09B). The key difference: Humana Inc is far larger — about 3.7× Aptiv PLC's market cap, and Humana Inc pays a 0.9% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | HUM | |
|---|---|---|
Market Cap | $12.82B | $47.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $409.42 |
52-Week Low | $52.57 | $163.67 |
Enterprise Value | $19.53B | $56.13B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.
Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.
Humana (HUM) trades at $392.22, down 1.39% on the day, with technical indicators showing a bullish trend despite near-term overbought signals. The company reported revenue growth to $129.66 billion in 2025 but faces margin compression, with net income margin declining to 0.82%. Recent news highlights strategic shifts, including the $900 million divestiture of its Gentiva stake and expansion of Medicaid contracts, while legal investigations into fiduciary duties and healthcare cost disclosures present headwinds.
The stock's outlook is mixed: bullish technicals and revenue growth contrast with margin pressures and legal risks. Analysts are cautious, with a consensus price target of $327.07 below the current price, suggesting limited upside. Investment opportunities lie in Humana's strategic focus on profitability and CenterWell growth, but risks include regulatory scrutiny and execution challenges in a competitive healthcare landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
